CRP and lung cancer: The type of malignancy (especially lung cancer); COPD; long-term ICI use; symptoms such as dyspnea, cough, and sputum; radiological detection of nodules or masses in the lung before ICI use; and laboratory parameters such as a low lymphocyte count, a low monocyte count, high CRP levels, and high a CLR were found to be associated with pulmonary toxicity.